Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Anbio Biotechnology Class A Ordinary Shares (NNNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NNNN (3-star) is a STRONG-BUY. BUY since 29 days. Profits (313.93%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $
Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 313.93% | Avg. Invested days 29 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 5.18 - 37.08 | Updated Date 05/15/2025 |
52 Weeks Range 5.18 - 37.08 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Anbio Biotechnology Class A Ordinary Shares
Company Overview
History and Background
Anbio Biotechnology (ANBO) is a biotechnology company focused on developing and commercializing innovative in-vitro diagnostic (IVD) products based on its microfluidic technology platform. Founded to address critical needs in rapid and accurate point-of-care diagnostics.
Core Business Areas
- Point-of-Care Testing (POCT): Development and commercialization of rapid, multiplexed diagnostic tests for infectious diseases, cardiac markers, and other conditions. These tests are designed for use in clinics, hospitals, and other point-of-care settings, enabling quick results and improved patient outcomes.
- Microfluidic Technology Platform: The company's core technology platform involves the use of microfluidics to automate and miniaturize diagnostic assays. This platform enables rapid, sensitive, and cost-effective testing with a small sample volume.
- Licensing and Partnerships: Anbio also engages in licensing its technology and forming strategic partnerships to expand the reach of its products and services globally.
Leadership and Structure
Key executives lead the company with expertise in diagnostics, technology, and business development. The company's structure likely includes R&D, manufacturing, sales/marketing, and regulatory affairs divisions.
Top Products and Market Share
Key Offerings
- Multiplexed Infectious Disease Panels: Anbio develops panels for rapid detection of multiple infectious diseases from a single sample. Market share data is difficult to obtain precisely, but competitors include Roche, Abbott, and QuidelOrtho in the broader IVD market. Revenue from this product is not publicly disclosed but key product.
- Cardiac Marker Tests: Rapid diagnostic tests for cardiac markers like troponin I, used in the diagnosis and management of acute myocardial infarction. Competitors include Siemens Healthineers and Beckman Coulter.
Market Dynamics
Industry Overview
The in-vitro diagnostics (IVD) market is experiencing growth due to aging populations, increasing prevalence of chronic diseases, and technological advancements in point-of-care testing. Increased demand for rapid and accurate diagnostic solutions at the point of care is a key trend.
Positioning
Anbio focuses on the POCT segment of the IVD market, leveraging its microfluidic technology to offer rapid, multiplexed diagnostic solutions. Its competitive advantage lies in speed, accuracy, and ease of use at the point of care.
Total Addressable Market (TAM)
The global IVD market is projected to reach hundreds of billions of USD. Anbio is positioned within the POCT segment, which constitutes a significant portion of the overall IVD market. Anbio targets growth within this focused area by creating specialized products.
Upturn SWOT Analysis
Strengths
- Microfluidic technology platform
- Rapid and multiplexed testing capabilities
- Focus on point-of-care diagnostics
- Strategic partnerships for market expansion
Weaknesses
- Limited brand recognition compared to established players
- Reliance on strategic partnerships for market access
- Potential regulatory hurdles for new diagnostic products
- Limited cash flow
Opportunities
- Expanding POCT market
- Increasing demand for multiplexed diagnostic testing
- Entering new geographic markets
- Developing new diagnostic panels for emerging diseases
Threats
- Competition from established IVD companies
- Changing regulatory landscape for diagnostic products
- Technological advancements by competitors
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Abbott (ABT)
- Siemens Healthineers (OTCQX:SMMNY)
- QuidelOrtho (QDEL)
Competitive Landscape
Anbio faces competition from established players with larger market share and brand recognition. Its advantages lie in its microfluidic technology and focus on multiplexed POCT. However, it needs to scale and execute effectively to compete.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are based on limited public information. Strategic partnerships suggest a focus on market expansion.
Future Projections: Future growth projections depend on various factors, including successful product development, regulatory approvals, and market penetration. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives may include new product launches, strategic partnerships, and expansions into new markets. Please refer to press releases for specifics.
Summary
Anbio Biotechnology is a POCT firm using microfluidic tech to address infectious diseases. While they're in a growing market, they must handle steep competition and regulatory requirements. Successful expansion and product innovation will be key for their continued growth in the IVD area. Key to their growth will be to build the brand.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Industry reports
- SEC filings of competitors
- Market research reports
Disclaimers:
The analysis is based on publicly available information and may not be comprehensive. Market share data is estimated and subject to change. Financial data may be limited. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anbio Biotechnology Class A Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-02-19 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 27 | Website https://www.anbio.com |
Full time employees 27 | Website https://www.anbio.com | ||
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.